Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Riboxx, CNBG unite in collaboration
April 2013
by Jeffrey Bouley  |  Email the author
SHARING OPTIONS:

RADEBEUL, Germany—A research collaboration has been announced between Riboxx Pharmaceuticals GmbH and China National Biotec Group Co. Ltd. (CNBG) to evaluate Riboxxim, Riboxx's TLR3 agonist, with an antigen from CNBG against an undisclosed infectious disease target. Under the terms of the collaboration, Riboxx will provide access to the compound while CNBG evaluates it in conjunction with its antigen against the disease target.
 
"We are delighted to initiate this collaboration with CNBG, which is one of the leading developers of vaccines against serious infectious diseases. Our TLR3 agonist has the potential to increase the efficacy of the antigen and provide a safe, but highly effective, immune response against the disease," Dr. Jacques Rohayem, CEO of Riboxx, said in a press release.  
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.